RA0672

antibody from Oursmab

Targeting: SELP CD62, CD62P, GMP140, GRMP, PADGEM, PSEL

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0672

Provider

Oursmab

Product name

Crizanlizumab (Biosimilar Reference Antibody) (SELP)

Antibody type

Monoclonal

Description

Crizanlizumab is a humanized monoclonal antibody approved for the prevention of vaso-occlusive crises (VOCs, or pain crises) in patients with sickle cell disease (SCD). Marketed under the brand name Adakveo?, it represents a novel therapeutic approach that targets a key pathway involved in the multicellular adhesion events that initiate vaso-occlusion. It is indicated for patients aged 16 years and older and is administered via intravenous infusion, typically on a monthly basis after an initial loading phase.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.